ASH: Adding Subcutaneous Daratumumab Slows Advanced Multiple Myeloma

TUESDAY, Dec. 8, 2020 -- For patients with relapsed/refractory multiple myeloma (RRMM), subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) reduces the risk of progression or death compared with Pd alone, according to a study...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news